- Joined
- Jun 26, 2012
- Messages
- 760
- Reaction score
- 514
First- sorry for the poor image quality.
Second- I am not an expert on this subject, and I'm sure there are aspects of these funding mechanisms I'm missing or not privy to.
This is a screen grab of a graph I made on the change in percentage of K08 grants (Clinician Investigator Awards) between 2009 and 2018 by institute and in aggregate. Data source is table 110 from the NIH RePORT, linked below.
Bottom Line:
% Change in number of transitional awards between 2009 and 2018 by code:
K01: +18.23%
K08: -17.08%
K99: +46.15%
R01: +26.89%
NIH Total (All Codes- K,R, etc) Award Funding: +7.98%
I used the 2009 number as the denomenator for calculating percent change. I linked the data source below for anyone to take a look at if curious.
I was surprised by the data here- while overall in this time span NIH budget increased, funding for K01's and K99's increased, and funding for R01's increased, the number of K08's has decreased. The number of awards in 2009 was 1,001 and is currently 830.
The news is not all bad here from the data. In the past two years, K08's have increased in number, hitting an all time low for the period in 2016 at 719, and gaining awards up to the 830 that were availiable in 2018. However, when compared to the other K awards (K01, K99) and R01 grants there is a net loss only for K08 Clinician Scientist - Transitional awards.
I'm curious to get other's input on what you think of this information. Are you encouraged by the gains in the last 2 years in the K08 category and do you expect it to continue? Why do you think K08's show a unique trend of decline compared to similar funding mechanisms for the past decade? Does this difference reflect a differential value placed on clinician vs traditional PhD scientists? All input is welcome and thanks for your time.
Data Source:
K Awards: https://report.nih.gov/FileLink.aspx?rid=533
R Awards: NIH Data Book
Last edited: